Most people haven’t heard of the condition, but Friedreich’s ataxia is getting more attention because of a new treatment and a large number of clinical trials enrolling people with the condition.
Early Genetic Testing Avoids Treatment Delays for Patients with Friedreich Ataxia
September 18th 2024Genetic and biochemical testing are crucial for improving outcomes for patients with Friedreich ataxia, according to speakers at a symposium at the European Association of Neurology Congress.
Read More
Lexeo Therapeutics' LX2006 Shows Promise in Treating Friedreich's Ataxia Cardiomyopathy
August 9th 2024Given the lack of approved treatments for FA cardiomyopathy, LX2006's potential could represent a breakthrough for patients suffering from a disease characterized by severe cardiac complications.
Read More
Everything You Need to Know About Larimar Therapeutics' Nomlabofusp and the FDA's START Program
August 7th 2024This past May, Larimar Therapeutics, a clinical-stage biotechnology company focused on developing treatments for rare diseases, announced that its lead compound for Friedreich's Ataxia, Nomlabofusp, would participate in the START pilot program. Nomlabofusp is one of the three Center for Drug Evaluation and Research programs and one of the six programs selected by the FDA.
Read More